{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T02:10:22Z","timestamp":1792030222679,"version":"4.4.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,1,31]],"date-time":"2021-01-31T00:00:00Z","timestamp":1612051200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,1,31]],"date-time":"2021-01-31T00:00:00Z","timestamp":1612051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s40273-020-00993-5","type":"journal-article","created":{"date-parts":[[2021,1,31]],"date-time":"2021-01-31T11:02:35Z","timestamp":1612090955000},"page":"579-587","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Multiple Myeloma in Portugal: Burden of Disease and Cost of Illness"],"prefix":"10.1007","volume":"39","author":[{"given":"Manuel","family":"Neves","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda","family":"Trigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bergantim","family":"Rui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Jo\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo","family":"L\u00facio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neves","family":"Mariana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8276-5610","authenticated-orcid":false,"given":"Hugo","family":"Pedrosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catarina","family":"Geraldes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,31]]},"reference":[{"key":"993_CR1","unstructured":"Institute, I. (2017) Medicines Use and Spending in the US."},{"key":"993_CR2","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1016\/S1470-2045(18)30090-1","volume":"19","author":"P Venkatesan","year":"2018","unstructured":"Venkatesan P. Cancer-related productivity losses in BRICS countries. Lancet Oncol. 2018;19:e147. https:\/\/doi.org\/10.1016\/S1470-2045(18)30090-1.","journal-title":"Lancet Oncol"},{"key":"993_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3332\/ecancer.2017.765","volume":"11","author":"JM Lopes","year":"2017","unstructured":"Lopes JM, Gon\u00e7alves FR, Borges M, Redondo P, Laranja-Pontes J. The cost of cancer treatment in Portugal. Ecancermedicalscience. 2017;11:1\u201310. https:\/\/doi.org\/10.3332\/ecancer.2017.765.","journal-title":"Ecancermedicalscience"},{"key":"993_CR4","doi-asserted-by":"publisher","first-page":"iv52","DOI":"10.1093\/annonc\/mdx096","volume":"28","author":"P Moreau","year":"2017","unstructured":"Moreau P, San Miguel J, Sonneveld P, Mateos MV, Zamagni E, Avet-Loiseau H, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv52-61. https:\/\/doi.org\/10.1093\/annonc\/mdx096.","journal-title":"Ann Oncol"},{"key":"993_CR5","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","volume":"4","author":"AJ Cowan","year":"2018","unstructured":"Cowan AJ, Allen C, Barac A, Basaleem H, Bensenor I, Curado MP, et al. Global burden of multiple myeloma. JAMA Oncol. 2018;4:1221. https:\/\/doi.org\/10.1001\/jamaoncol.2018.2128.","journal-title":"JAMA Oncol"},{"key":"993_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.6004\/jnccn.2018.0002","volume":"16","author":"SK Kumar","year":"2018","unstructured":"Kumar SK, Callander NS, Alsina M, et al. NCCN Guidelines Insights: multiple myeloma, version 3. 2018. J Natl Compr Cancer Netw. 2018;16:11\u201320. https:\/\/doi.org\/10.6004\/jnccn.2018.0002.","journal-title":"J Natl Compr Cancer Netw."},{"key":"993_CR7","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/ejh.13044","volume":"100","author":"J Ashcroft","year":"2018","unstructured":"Ashcroft J, Duran I, Hoefeler H, et al. Healthcare resource utilisation associated with skeletal-related events in European patients with multiple myeloma: Results from a prospective, multinational, observational study. Eur J Haematol. 2018;100:479\u201387. https:\/\/doi.org\/10.1111\/ejh.13044.","journal-title":"Eur J Haematol"},{"key":"993_CR8","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.3324\/haematol.2014.117176","volume":"100","author":"E Terpos","year":"2015","unstructured":"Terpos E, Kleber M, Engelhardt M, et al. European myeloma network guidelines for the management of multiple myeloma-related complications. Haematologica. 2015;100:1254\u201366. https:\/\/doi.org\/10.3324\/haematol.2014.117176.","journal-title":"Haematologica"},{"key":"993_CR9","doi-asserted-by":"publisher","DOI":"10.1111\/ecc.13026","author":"L Antunes","year":"2019","unstructured":"Antunes L, Rocha-Gon\u00e7alves F, Chacim S, Lef\u00e8vre C, Pereira M, Pereira S, et al. Real-world treatment patterns, resource use and cost burden of multiple myeloma in Portugal. Eur J Cancer Care. 2019. https:\/\/doi.org\/10.1111\/ecc.13026.","journal-title":"Eur J Cancer Care."},{"key":"993_CR10","volume-title":"World development report 1993: \u2018Investing in Health\u2019","author":"RA Lea","year":"1993","unstructured":"Lea RA. World development report 1993: \u2018Investing in Health.\u2019 Milton: Taylor & Francis; 1993."},{"key":"993_CR11","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/S0140-6736(96)07495-8","volume":"72","author":"CJL Murray","year":"1994","unstructured":"Murray CJL. Global burden of disease Le poids de la morbidite dans le monde quantifying the burden of disease\u202f: the technical basis for disability-adjusted life years. Bull World Health Organ. 1994;72:429\u201345. https:\/\/doi.org\/10.1016\/S0140-6736(96)07495-8.","journal-title":"Bull World Health Organ"},{"key":"993_CR12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1478-7954-10-19","volume":"10","author":"SA Schroeder","year":"2012","unstructured":"Schroeder SA. Incidence, prevalence, and hybrid approaches to calculating disability-adjusted life years. Popul Health Metr. 2012;10:19. https:\/\/doi.org\/10.1186\/1478-7954-10-19.","journal-title":"Popul Health Metr"},{"key":"993_CR13","unstructured":"ECIS\u2014European Cancer Information System. Estimates of cancer incidence and mortality in 2018, for all countries. 2018. https:\/\/ecis.jrc.ec.europa.eu\/index.php."},{"key":"993_CR14","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.seps.2014.12.002","volume":"49","author":"A Chen","year":"2015","unstructured":"Chen A, Jacobsen KH, Deshmukh A, Cantor SB. The evolution of the disability-adjusted life year (DALY). Soc Econ Plan Sci. 2015;49:10\u20135. https:\/\/doi.org\/10.1016\/j.seps.2014.12.002.","journal-title":"Soc Econ Plan Sci"},{"key":"993_CR15","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/leu.2013.313","volume":"28","author":"SK Kumar","year":"2014","unstructured":"Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28:1122\u20138. https:\/\/doi.org\/10.1038\/leu.2013.313.","journal-title":"Leukemia"},{"key":"993_CR16","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/j.1524-4733.2007.00210.x","volume":"11","author":"G Clabaugh","year":"2008","unstructured":"Clabaugh G, Ward MM. Cost-of-illness studies in the United States: a systematic review of methodologies used for direct cost. Value Health. 2008;11:13\u201321.","journal-title":"Value Health"},{"key":"993_CR17","unstructured":"Sa\u00fade Minist\u00e9rio. Circular Normativa N. 8\/2018\/DPS\/ACSS. Hospital Framework Contract 2018:1\u20136. 2019. www.acss.min-saude.pt\/wp-content\/uploads\/2018\/07\/Circular_Normativa_8_2018.pdf."},{"key":"993_CR18","unstructured":"Di\u00e1rio da Rep\u00fablica. Portaria no. 254\/2018. NHS Price lists. 2018. https:\/\/dre.pt\/home\/-\/dre\/116353279\/details\/maximized."},{"key":"993_CR19","unstructured":"Sa\u00fade Minist\u00e9rio. Despacho no. 7702-A\/2012. 2012: 20410. NHS Transport fees. 2012."},{"key":"993_CR20","unstructured":"World Health Organization (WHO). International Agency for Research on Cancer. Estimated number of deaths in 2018, multiple myeloma, both sexes, all ages. Cancer Today. 2018:2018. https:\/\/gco.iarc.fr\/today\/home."},{"key":"993_CR21","unstructured":"Diabetes ON. Relat\u00f3rio do Observat\u00f3rio Nacional da Diabetes. 2016."},{"key":"993_CR22","doi-asserted-by":"crossref","unstructured":"Evaluation, I. for H.M. and. Global Burden of Disease Compare. 2020.","DOI":"10.1093\/med\/9780190082543.001.0001"},{"issue":"1","key":"993_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.repc.2014.08.005","volume":"34","author":"M Gouveia","year":"2015","unstructured":"Gouveia M, Costa J, Alarc\u00e3o J, et al. (2015) Burden of disease and cost of illness of atrial fibrillation in Portugal. Rev Port Cardiol. 2015;34(1):1\u201311.","journal-title":"Rev Port Cardiol"},{"key":"993_CR24","doi-asserted-by":"publisher","first-page":"e193","DOI":"10.1177\/030089161309900434","volume":"99","author":"MT Petrucci","year":"2013","unstructured":"Petrucci MT, Calabrese E, Levi A, et al. Cost of illness in patients with multiple myeloma in Italy: the CoMiM study. Tumori. 2013;99:e193-202. https:\/\/doi.org\/10.1177\/030089161309900434.","journal-title":"Tumori"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-020-00993-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-020-00993-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-020-00993-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T20:54:22Z","timestamp":1697748862000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-020-00993-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,31]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["993"],"URL":"https:\/\/doi.org\/10.1007\/s40273-020-00993-5","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,31]]},"assertion":[{"value":"24 December 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"RB, MN, MN HP and PL collected data, designed and developed the analysis and wrote and reviewed the manuscript. CG, CJ, FT and JM critically reviewed the analysis of the data and its design and reviewed the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"This study was developed by the Portuguese Group of Multiple Myeloma (Grupo Portugu\u00eas de Mieloma M\u00faltiplo) and funded by Janssen Portugal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Manuel Neves has received honoraria for speaking and\/or participation in advisory boards for Janssen, Takeda, Amgen and Celgene. Fernanda Trigo has received honoraria for speaker services from Takeda, Amgen, Celgene and Janssen and for attendance at advisory boards from Takeda, Amgen, Celgene and Janssen. Rui Bergantim has received research grants from APCL\/SPH\/AMGEN and Celgene and honoraria for speaking and\/or participation in advisory boards from Celgene, Janssen, Takeda and Amgen. Cristina Jo\u00e3o has received a research grant from Takeda and honoraria for speaking and\/or participation in advisory boards from Celgene, Janssen, Takeda, AbbVie and Amgen. Paulo L\u00facio has received honoraria for speaking and\/or participation in advisory boards from Celgene, Janssen, Takeda and Amgen. Mariana Neves and Hugo Pedrosa are employees of IQVIA Solutions Portugal. Jo\u00e3o Mendes is an employee of Janssen Cilag Farmac\u00eautica, Portugal. Catarina Geraldes has received honoraria from Janssen, Celgene, Amgen, Gilead and Takeda for lectures and participation in advisory boards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Data used for this study relied on two main data sources to support the quantification of the burden and cost of MM: the NHS 2016 DRG dataset and the 2013\u20132018 drug longitudinal retrospective hospital patient dataset of IQVIA Consulting. These datasets are not publicly available and were acquired for the development of this study. Data used are presented in aggregate in this paper. Other public data sources used in the development of this study are disclosed in the reference list.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}}]}}